Among 2,338 chronic hepatitis B patients followed during 2006-2013 in the Chronic Hepatitis Cohort Study, 78% had ≥1 alanine aminotransferase and 37% had ≥1 HBV DNA level assessed annually. Among cirrhotic patients, 46% never had hepatic imaging. Patients in this cohort were insufficiently monitored for disease activity and hepatocellular carcinoma.
Introduction
In the United States (U.S.), the National Health and Nutrition Examination Survey identified approximately 850,000 noninstitutionalized persons with chronic hepatitis B (CHB) during 2011-2012, when, for the first time, non-Hispanic Asians were oversampled in the survey [1] . CHB is a dynamic condition, the evolution of which is influenced by viral and host factors, and its course is variable among those afflicted. CHB is considered to consist of four phases, which depend primarily upon serum levels of alanine aminotransferase (ALT) and hepatitis B virus (HBV) DNA [2, 3] . Given the variable evolution and manifestation of phases, all CHB patients should undergo serial assessment of these laboratory indicators during the course of follow-up [2, [4] [5] [6] .
Little is known about the degree to which HBV-infected persons with access to integrated healthcare in the U.S.
are continually monitored for disease activity (to determine suitability for antiviral therapy) and for serious complications, such as hepatocellular carcinoma (HCC). What evidence exists suggests that the frequency of clinical monitoring falls short of guideline-based recommendations, even among patients who receive care in large specialty clinics affiliated with academic centers, and in the Veterans Administration system [7] [8] [9] [10] .
In this analysis we examined data collected from patients with confirmed CHB in the Chronic Hepatitis Cohort Study (CHeCS) to determine the frequency with which patients were monitored for disease activity and for HCC.
Methods

Study population: Chronic hepatitis B cohort
We used data collected from patients with confirmed chronic hepatitis B enrolled in the CHeCS, a multi-center observational study whose composition and criteria for inclusion have been summarized previously [11] . These data were accessed via electronic health records and administrative systems (supplemented with individual chart review by trained data abstractors) collected during 2006 through 2013 from persons aged ≥18 years at four sites: Geisinger Health System, Danville, PA; Henry Ford Health System, Detroit, MI; Kaiser PermanenteNorthwest, Portland, OR; and Kaiser Permanente-Honolulu, Hawaii. The study protocol was reviewed by an 
Statistical analysis
CHB patients identified with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus coinfection were subsequently excluded from further analysis, as were those who developed HCC or had a liver transplant before commencement of the study period. To ensure sufficient follow-up time to examine the frequency of clinical assessment, we also excluded patients with less than 12 months of follow-up at any of the four study sites.
We then determined the frequency of clinical assessment of disease status, defined as the proportion of patients with ≥1 ALT and HBV DNA determination per year of follow-up during the study period. Among those with cirrhosis, the proportion of patients who had a hepatic imaging study (ultrasound, computed tomography, or magnetic resonance imaging) per year of study period follow-up. These frequency determinations were stratified according to patient sociodemographic characteristics at the initiation of follow-up, treatment status, A c c e p t e d M a n u s c r i p t 5 and whether a patient had received hepatitis-related specialty care. We also examined the frequency of HBV DNA testing within 60 days after an elevated ALT level (i.e., elevated according to the upper limit of normal of the laboratory performing the test).
We ascertained the presence of cirrhosis among patients by any of the following means: 1) a liver biopsy result consistent with Metavir F4, 2) a FIB4 score >5.17 (a score cutoff previously validated [12]), or 3) ICD-9 codes consistent with either compensated or decompensated cirrhosis [13] .
Results
The initial cohort comprised 2,992 patients with CHB. After excluding patients with coinfection, previous HCC diagnosis or liver transplant, or <12 months of follow-up, 2,338 patients remained for assessment of clinical monitoring; median follow-up was 6.3 years, providing more than 14,000 person-years of observation. The Table shows had private health insurance (75%), had not been prescribed treatment (68%), and had received liver-related specialty care (72%).
ALT monitoring
Of 2,338 patients in the cohort, 1,814 (78%) had at least one ALT level obtained per year of follow-up. There were significant differences in the proportion of patients who had at least annual ALT measured according to study site, age group, sex, race/ethnicity, insurance status, treatment prescription status, and whether they had received hepatitis-related specialty care. Compared to their categorical counterparts, patients more likely to have had at least one ALT level measured per year of follow-up were aged ≥60 years (91%), male (85%), white (82%), had Medicare plus supplemental private insurance (94%), were prescribed treatment (92%), and received liver-related specialty care (85%). 
Assessment and care of patients with cirrhosis
Among patients in the cohort, 547 (24%) were classified with cirrhosis: 52 (10%) had a Metavir F4 result on liver biopsy, 464 (85%) had an ICD-9 code consistent with cirrhosis, and 196 (36%) had a FIB4 score >5.17. Among those with cirrhosis, 297 (54%) had HBV DNA testing done at least annually, 189 (35%) had testing done but less frequently than annually, and 61 (11%) never had an HBV DNA test done. Of these 547 patients, 289 (53%) had at least one hepatic imaging study (primarily ultrasound) during follow-up. Among those who had at least one imaging study, only 79 (27%) had an imaging study performed at least annually; therefore, among the 547 patients with cirrhosis, only 14% had annual hepatic imaging studies performed.
Prescription of antiviral therapy in the CHB cohort
Of the 2,338 patients in the cohort, 737 (32%) were prescribed HBV antiviral therapy; of those treated, 305 (41%) had cirrhosis, 460 (62%) had an HBV DNA >2,000 IU/mL and an elevated ALT before treatment initiation, 126 (17%) had a liver biopsy with a result of Metavir F2-F4, and 69 (9%) had none of three preceding characteristics. Of the 547 patients with cirrhosis, 305 (56%) were prescribed HBV antiviral therapy. 
Discussion
In this large cohort of patients with a median of 6 years of follow-up within integrated health care organizations in the US during 2006-2013, we found that CHB patients had suboptimal clinical monitoring and, accordingly, insufficient data to determine disease phase and antiviral treatment eligibility; 32% of the cohort were prescribed treatment. Although the majority of patients had ALT levels assessed at least annually, only onethird of all CHB patients were assessed annually for HBV DNA levels (and only half of cirrhotics had annual testing); 18% of the cohort never had an HBV DNA level assessed during their entire follow-up. In gauging the frequency of surveillance for HCC among at-risk CHB patients, we found that nearly 50% of CHB patients with cirrhosis never had a hepatic imaging study during follow-up, and only 15% of patients with cirrhosis had imaging performed at least annually.
This analysis has some limitations. Clinical monitoring practices at our four study sites might not reflect those in other general healthcare settings; however, an advantage of the CHeCS is that it examines the provision of care in a real-world environment at four large healthcare organizations that are geographically and demographically disparate. We did not have access to family history and we did not include age to determine the pool of high risk patients eligible for HCC surveillance, in addition to those with cirrhosis; therefore, the assessment frequency based on cirrhosis alone likely represents a conservative estimate.
In summary, we found that patients in our cohort were insufficiently monitored for disease status, and among those with cirrhosis, for HCC and viremia. Our findings reiterate the need for clinicians who treat patients with CHB to provide ongoing, continual assessment of disease activity based on HBV DNA and ALT levels, as well as liver imaging surveillance among patients at high risk for HCC. As antiviral therapy for CHB now includes potent and highly efficacious oral agents that have few contraindications and minimal side effects, as well as a high barrier to resistance, clinicians should be vigilant for opportunities to decrease the likelihood of poor clinical outcomes. 
